Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - Rovin, Brad H; Barratt, Jonathan; Heerspink, Hiddo J. L.; Alpers, Charles E.; Bieler, Stewart; Chae, Dong-Wan; Diva, Ulysses A.; Floege, Juergen; Gesualdo, Loreto; Inrig, Jula K.; Noronha, Irene de Lourdes (LANCET, 2023)